title: Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif.
abstract: Arginine-glycine-aspartate (RGD) has been shown to be essential for the recognition of integrins overexpressed in tumor cells, especially during tumor invasion, angiogenesis, and metasis. In this study, a novel tetrapeptide, RGD-valine (RGDV), was designed and attached to the N position of 1-β-D-arabinofuranosylcytosine (Ara-C) at the valine end, as a homing device for the delivery of Ara-C to tumor cells. Furthermore, fatty acids of various chain lengths (C(n)H(2n+1)COOH, n = 7, 9, 11, 13, and 15) were attached to the arginine end of RGDV to form a series of C(n)H(2n+1)CO-RGDV-Ara-C compounds. The structures of C(n)H(2n+1)CO-RGDV-Ara-C compounds were confirmed using mass spectrometry and nuclear magnetic resonance. The liposomal preparations of the synthesized C(n)H(2n+1)CO-RGDV-Ara-C compounds were obtained using the film dispersion method in the presence of phospholipids. The particle size, zeta potential, and dispersity index of the liposomes formed were found to be approximately 215 nm (diameter), approximately -30 mV, and <0.3, respectively. The antitumor activity of the liposomal preparations containing the respective C(n)H(2n+1)CO-RGDV-Ara-C compounds was evaluated in mice inoculated with sarcoma S(180). Liposomal Ara-C preparation, liposomal C(11)H(23)CO-V-Ara-C preparation, Ara-C, and C(11)H(23)CO-V-Ara-C sodium carboxymethyl cellulose (CMC-Na) suspensions were used as controls. C(n)H(2n+1)CO-RGDV-Ara-C containing liposomal preparations were shown with an enhanced antitumor activity, likely because of the targeting effect of RGDV.
authors.affiliation: School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Wang
authors.forename: Chunying
authors.initials: C
authors.lastname: Cui
authors.forename: Zhao
authors.initials: Z
authors.lastname: Ren
authors.forename: Lili
authors.initials: L
authors.lastname: Wang
authors.forename: Hu
authors.initials: H
authors.lastname: Liu
authors.forename: Guohui
authors.initials: G
authors.lastname: Cui
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D008081:Liposomes / Q000737:chemistry*; D008297:Male; D051379:Mice; D009842:Oligopeptides / Q000737:chemistry*; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000964:Antimetabolites, Antineoplastic; D008081:Liposomes; D009842:Oligopeptides; D003561:Cytarabine; C047981:arginyl-glycyl-aspartic acid